288 related articles for article (PubMed ID: 8850108)
41. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction.
Goldman L; Sia ST; Cook EF; Rutherford JD; Weinstein MC
N Engl J Med; 1988 Jul; 319(3):152-7. PubMed ID: 2898733
[TBL] [Abstract][Full Text] [Related]
42. Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease.
Plosker GL; McTavish D
Drugs Aging; 1995 Sep; 7(3):226-53. PubMed ID: 8535052
[TBL] [Abstract][Full Text] [Related]
43. [Treatment of acute myocardial infarction with oral captopril. A randomized, double blind and placebo controlled pilot study].
Lu CY
Zhonghua Xin Xue Guan Bing Za Zhi; 1993 Apr; 21(2):74-6, 121-2. PubMed ID: 8223165
[TBL] [Abstract][Full Text] [Related]
44. Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS).
Chan PS; Soto G; Jones PG; Nallamothu BK; Zhang Z; Weintraub WS; Spertus JA
Circulation; 2009 Jan; 119(3):398-407. PubMed ID: 19139382
[TBL] [Abstract][Full Text] [Related]
45. [The SMILE study: the rationale, design, organization and definition of the objectives. Survival of Myocardial Infarction Long-term Evaluation].
Ambrosioni E; Borghi C; Magnani B
Ann Ital Med Int; 1993; 8(4):230-4. PubMed ID: 8161479
[TBL] [Abstract][Full Text] [Related]
46. Captopril in the management of patients after acute myocardial infarctions. A cost effectiveness analysis in Italy.
Mantovani LG; Belisari A; Szucs TD
Pharmacol Res; 1998 May; 37(5):345-51. PubMed ID: 9642029
[TBL] [Abstract][Full Text] [Related]
47. Pharmacoeconomics of angiotensin converting enzyme inhibitors in heart failure.
Szucs TD
Am J Hypertens; 1997 Oct; 10(10 Pt 2):272S-279S. PubMed ID: 9366284
[TBL] [Abstract][Full Text] [Related]
48. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.
Pfeffer MA; Braunwald E; Moyé LA; Basta L; Brown EJ; Cuddy TE; Davis BR; Geltman EM; Goldman S; Flaker GC
N Engl J Med; 1992 Sep; 327(10):669-77. PubMed ID: 1386652
[TBL] [Abstract][Full Text] [Related]
49. The cost-effectiveness of losartan versus captopril in patients with symptomatic heart failure.
Dasbach EJ; Rich MW; Segal R; Gerth WC; Carides GW; Cook JR; Murray JF; Snavely DB; Pitt B
Cardiology; 1999; 91(3):189-94. PubMed ID: 10516413
[TBL] [Abstract][Full Text] [Related]
50. Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction? Results of one-year serial echocardiographic follow-up from the Captopril and Thrombolysis Study (CATS).
van Gilst WH; Kingma JH; Peels KH; Dambrink JH; St John Sutton M
J Am Coll Cardiol; 1996 Jul; 28(1):114-21. PubMed ID: 8752803
[TBL] [Abstract][Full Text] [Related]
51. An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors.
Taylor M; Scuffham PA; Chaplin S; Papo NL
Value Health; 2009 Jun; 12(4):459-65. PubMed ID: 19192258
[TBL] [Abstract][Full Text] [Related]
52. [Cost/benefit relations: evaluation of inpatient and ambulatory rehabilitation].
Kübler W; Niebauer J; Kreuzer J
Z Kardiol; 1994; 83 Suppl 6():151-8. PubMed ID: 7863688
[TBL] [Abstract][Full Text] [Related]
53. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.
Dickstein K; Kjekshus J;
Lancet; 2002 Sep; 360(9335):752-60. PubMed ID: 12241832
[TBL] [Abstract][Full Text] [Related]
54. Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure.
Croom KF; Plosker GL
Pharmacoeconomics; 2005; 23(10):1057-72. PubMed ID: 16235978
[TBL] [Abstract][Full Text] [Related]
55. Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The Netherlands.
Michel BC; Al MJ; Remme WJ; Kingma JH; Kragten JA; van Nieuwenhuizen R; van Hout BA
Eur Heart J; 1996 May; 17(5):731-40. PubMed ID: 8737104
[TBL] [Abstract][Full Text] [Related]
56. Additional beneficial effects of canrenoate in patients with anterior myocardial infarction on ACE-inhibitor treatment. A pilot study.
Di Pasquale P; Cannizzaro S; Giubilato A; Vitrano MG; Scandurra A; Giambanco F; Saccone G; Sarullo FM; Paterna S
Ital Heart J; 2001 Feb; 2(2):121-9. PubMed ID: 11256540
[TBL] [Abstract][Full Text] [Related]
57. [A cost-effectiveness analysis of prognostic studies in acute uncomplicated myocardial infarct].
Bermejo B; Candell Riera J; Olona M; Rosselló J; Vaqué J; Permanyer Miralda G; Castell J; Soler Soler J
Rev Esp Cardiol; 1993 Aug; 46(8):477-82. PubMed ID: 8378564
[TBL] [Abstract][Full Text] [Related]
58. [Captopril in the treatment of heart failure].
Herold M
Vnitr Lek; 1995 Mar; 41(3):161. PubMed ID: 7762168
[TBL] [Abstract][Full Text] [Related]
59. The economics of TRACE. A cost-effectiveness analysis of trandolapril in postinfarction patients with left ventricular dysfunction.
LePen C; Lilliu H; Keller T; Fiessinger S
Pharmacoeconomics; 1998 Jul; 14(1):49-58. PubMed ID: 10182194
[TBL] [Abstract][Full Text] [Related]
60. The effect of pindolol on the two years mortality after complicated myocardial infarction.
Eur Heart J; 1983 Jun; 4(6):367-75. PubMed ID: 6617682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
